Septra (Trimethoprim-Sulfamethoxazole / TMP-SMX / Co-trimoxazole): UTI, PCP & MRSA Pharmacology

Septra (Trimethoprim-Sulfamethoxazole / TMP-SMX / Co-trimoxazole, ATC Code J01EE01) is a fixed-dose (1:5 ratio) synergistic antimicrobial combination that blocks two consecutive enzymatic steps in bacterial tetrahydrofolate biosynthesis:

1. Sulfamethoxazole (SMX, 800 mg in DS): A sulfonamide structural analog of para-aminobenzoic acid (PABA) that competitively inhibits bacterial dihydropteroate synthase (DHPS), preventing dihydrofolic acid formation.
2. Trimethoprim (TMP, 160 mg in DS): Selectively inhibits bacterial dihydrofolate reductase (DHFR) with >50,000-fold higher affinity for bacterial vs. mammalian DHFR, halting purine, thymidine, and methionine synthesis.

Primary Clinical Indications

• Acute Uncomplicated Cystitis & Pyelonephritis: First-line oral therapy (1 Septra DS tablet [160/800 mg] twice daily for 3 days in uncomplicated female cystitis, or 14 days in culture-susceptible pyelonephritis) where local E. coli resistance rates are <20%.
• Community-Associated MRSA Skin & Soft Tissue Infections: High bactericidal activity against CA-MRSA cellulitis and cutaneous abscesses.
• Pneumocystis jirovecii Pneumonia (PJP / PCP) & Toxoplasmosis: Gold-standard agent for both treatment (15–20 mg/kg/day of TMP component in divided doses) and prophylaxis in immunocompromised hosts.

Clinical Laboratory Monitoring (Potassium & Serum Creatinine)

Trimethoprim is structurally related to potassium-sparing diuretics (amiloride) and blocks epithelial sodium channels (ENaC) in the distal nephron, which can cause reversible hyperkalemia and competitive inhibition of tubular creatinine secretion (producing a benign 10–15% rise in serum creatinine without true GFR decline).